Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02303405 · ClinicalTrials.gov registry record · Phase 2
Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Charles Drew University of Medicine and Science.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT02303405: Clinical Trial Phase 2 study, sponsored by Charles Drew University of Medicine and Science.
NCT02303405 is a Phase 2 study that was terminated before completion, run by Charles Drew University of Medicine and Science. The registered enrollment target is 22 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02303405, a Phase 2 study, was terminated before completion, sponsored by Charles Drew University of Medicine and Science.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
A 4-month, randomized, prospective, open-label comparison trial of hydroxychloroquine vs. pioglitazone in type 2 diabetic patients inadequately controlled on maximally tolerated doses of metformin plus a sulfonylurea.
Primary Outcome
Glycemic control
Interventions
- DRUG Pioglitazone
- DRUG Hydroxychloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2014-11 |
| Est. Completion | 2017-11 |
| Phase | Phase 2 |
Why NCT02303405 stopped before completion
NCT02303405 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which Pioglitazone is the first listed.
NCT02303405 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02303405 about?
NCT02303405 is a clinical study titled "Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus". A 4-month, randomized, prospective, open-label comparison trial of hydroxychloroquine vs. pioglitazone in type 2 diabetic patients inadequately controlled on maximally tolerated doses of metformin plus a sulfonylurea.
What is the current status of trial NCT02303405?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2014-11. Estimated completion is 2017-11.
What interventions are being tested in trial NCT02303405?
The interventions under investigation include: Pioglitazone (DRUG), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT02303405?
This trial is sponsored by Charles Drew University of Medicine and Science, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02303405's enrollment target sits among peer trials
22 1790th of 2000 higher than 207 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia